AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17265483 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by Adalimumab (for 24 weeks)
Number of subjects: 151
Study 15860855 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant anthracycline-based chemotherapy
Number of subjects: 937
Study 15860855 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 937
Study 12576934 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxifluridine 1,000 mg/m²/d plus leucovorin 30 mg/d on days 1 to 7 and 15 to 21 of each cycle (group A)
Number of subjects: 77
Study 12576934 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 5‐fluorouracil 400 mg/m²/d plus leucovorin 20 mg/m²/d on days 1‐5 of each cycle (group B)
Number of subjects: 77
Study 10220204 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 i.u. daily oral alpha-tocopherol for 8 weeks
Number of subjects: 48
Study 10220204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 9015560 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavor conditioning (CS+ with facial expression of dislike)
Number of subjects: 0
Study 9015560 — intervention group
Group type: COMPARATOR
Intervention: Color conditioning (CS- with facial expression of dislike)
Number of subjects: 0
Study 9015560 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drinks with local context cues (colors)
Number of subjects: 0
Study 9015560 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit beliefs in CS = Flavor groups
Number of subjects: 0
Study 9015560 — intervention group
Group type: COMPARATOR
Intervention: Explicit beliefs in CS = Color groups
Number of subjects: 0
Study 1340687 — intervention group
Group type: COMPARATOR
Intervention: 500 micrograms BIM (continuous s.c. infusion for 24 hours)
Number of subjects: 10
Study 1340687 — intervention group
Group type: COMPARATOR
Intervention: 1500 micrograms/24h BIM (as 500 micrograms x 3 s.c. injections, 750 micrograms x 2 s.c. injections, and continuous s.c. infusion)
Number of subjects: 10
Study 1340687 — intervention group
Group type: COMPARATOR
Intervention: 30 mg IM of a long acting formulation of BIM
Number of subjects: 10
Study 6426075 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin and gentamicin
Number of subjects: 20
Study 6426075 — intervention group
Group type: COMPARATOR
Intervention: Carbenicillin and gentamicin
Number of subjects: 20
Study 31279613 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered psycho-education with behavioral activation intervention (TBA)
Number of subjects: 96
Study 31279613 — intervention group
Group type: COMPARATOR
Intervention: Telephone-based psycho-education with general monitoring (TGM)
Number of subjects: 96
Study 30343626 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS) screening
Number of subjects: 0
Study 30343626 — intervention group
Group type: EXPERIMENTAL
Intervention: Model predictions for CRC incidence and mortality
Number of subjects: 0
Study 30343626 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-detected cancers
Number of subjects: 0
Study 30343626 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-detected adenomas
Number of subjects: 0
Study 27035159 — intervention group
Group type: EXPERIMENTAL
Intervention: edivoxetine 12 mg + SSRI
Number of subjects: 231
Study 27035159 — intervention group
Group type: EXPERIMENTAL
Intervention: edivoxetine 18 mg + SSRI
Number of subjects: 231
Study 27035159 — intervention group
Group type: COMPARATOR
Intervention: placebo + SSRI
Number of subjects: 231
Study 27035159 — intervention group
Group type: EXPERIMENTAL
Intervention: edivoxetine 12-18 mg + SSRI
Number of subjects: 231
Study 27035159 — intervention group
Group type: EXPERIMENTAL
Intervention: edivoxetine 6 mg + SSRI
Number of subjects: 231
Study 25301963 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM group (n = 22)
Number of subjects: 52
Study 22156967 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (5 sessions of 2 hours each focused on sexual risk-reduction information and exercises)
Number of subjects: 283
Study 22156967 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV counseling and testing (baseline)
Number of subjects: 283
Study 19889829 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy-supplemented diet
Number of subjects: 20
Study 19889829 — intervention group
Group type: COMPARATOR
Intervention: Soy-supplemented diet
Number of subjects: 20
Study 18028017 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (5 years treatment)
Number of subjects: 0
Study 18028017 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (5 years treatment)
Number of subjects: 0
Study 16187009 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg daily for 4 weeks
Number of subjects: 35
Study 16187009 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg daily for 4 weeks
Number of subjects: 35
Study 12097809 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 million IU IFN‐beta‐1b
Number of subjects: 8
Study 12097809 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 8
Study 9933696 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia (TEA) with 2% lidocaine (15-20 ml), midazolam (5-10 mg), and fentanyl (<250 microg)
Number of subjects: 64
Study 9933696 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia (TEA)
Number of subjects: 64
Study 9933696 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 64
Study 7485941 — intervention group
Group type: EXPERIMENTAL
Intervention: dopexamine
Number of subjects: 16
Study 7485941 — intervention group
Group type: COMPARATOR
Intervention: dobutamine
Number of subjects: 16
Study 2305976 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA (Patient-Controlled Epidural Analgesia)
Number of subjects: 58
Study 2305976 — intervention group
Group type: COMPARATOR
Intervention: CIT (Conventional Intermittent 'Top-Up' Injections)
Number of subjects: 58
Study 7272395 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger temperature biofeedback
Number of subjects: 12
Study 7272395 — intervention group
Group type: COMPARATOR
Intervention: Guided imagery
Number of subjects: 12
Study 30226009 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis (3 sessions)
Number of subjects: 120
Study 30226009 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis (habitual users)
Number of subjects: 120
Study 30226009 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Number of subjects: 120
Study 28374969 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous-timed (ST) mode
Number of subjects: 13
Study 28374969 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous (S) mode
Number of subjects: 13
Study 25747263 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with a dose prescription of 35 Gy in five fractions
Number of subjects: 70
Study 25747263 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-optimized plans
Number of subjects: 70
Study 24220385 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscrews in the retromolar area
Number of subjects: 19
Study 24220385 — intervention group
Group type: COMPARATOR
Intervention: Miniscrews in the posterior area of the maxillary
Number of subjects: 19
Study 20359590 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay to PCI >24 h
Number of subjects: 7749
Study 20359590 — intervention group
Group type: COMPARATOR
Intervention: Delay to PCI <8 h
Number of subjects: 7749
Study 20359590 — intervention group
Group type: COMPARATOR
Intervention: Delay to PCI 8 to 24 h
Number of subjects: 7749
Study 18991820 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiatherogenic diet with sour milk product Danacor enriched with phytosterols
Number of subjects: 0
Study 15665710 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-uninfected children
Number of subjects: 1118
Study 15665710 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected children
Number of subjects: 1118
Study 12845486 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET
Number of subjects: 53
Study 12845486 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 53
Study 11083748 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin (0.05 microgram/kg/min)
Number of subjects: 13
Study 11083748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8853765 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine (Asacol 1.6 g daily)
Number of subjects: 15
Study 8853765 — intervention group
Group type: COMPARATOR
Intervention: Olsalazine (Dipentum 1.0 g daily)
Number of subjects: 15
Study 1627817 — intervention group
Group type: EXPERIMENTAL
Intervention: XRT
Number of subjects: 0
Study 1627817 — intervention group
Group type: COMPARATOR
Intervention: MRM
Number of subjects: 0
Study 6378159 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine hydrochloride with 1:200,000 epinephrine
Number of subjects: 0
Study 6378159 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine hydrochloride with 1:200,000 epinephrine
Number of subjects: 0
Study 31056954 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor Walking Training (OWT)
Number of subjects: 16
Study 31056954 — intervention group
Group type: COMPARATOR
Intervention: Cycle Ergometer Training (CT)
Number of subjects: 16
Study 29195028 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicocelectomy
Number of subjects: 120
Study 29195028 — intervention group
Group type: EXPERIMENTAL
Intervention: Mast cell stabilizer (1 mg ketotifen twice daily for three months)
Number of subjects: 120
Study 29195028 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicocelectomy followed by mast cell stabilizer (1 mg ketotifen twice daily for three months)
Number of subjects: 120
Study 29195028 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 120
Study 27067196 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP), administered monthly from 6 to 24 months of age.
Number of subjects: 177
Study 24867434 — intervention group
Group type: EXPERIMENTAL
Intervention: Low perceived required effort
Number of subjects: 120
Study 24867434 — intervention group
Group type: COMPARATOR
Intervention: High perceived required effort
Number of subjects: 120
Study 24867434 — intervention group
Group type: EXPERIMENTAL
Intervention: Support available
Number of subjects: 120
Study 24867434 — intervention group
Group type: COMPARATOR
Intervention: Support not available
Number of subjects: 120
Study 22305890 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin in combination with carboplatin
Number of subjects: 1
Study 22305890 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 1
Study 22305890 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin and carboplatin
Number of subjects: 1
Study 20561549 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) use group
Number of subjects: 55
Study 20561549 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 18028873 — intervention group
Group type: EXPERIMENTAL
Intervention: Group debriefing (67 participants)
Number of subjects: 119
Study 18028873 — intervention group
Group type: COMPARATOR
Intervention: Control group (52 participants)
Number of subjects: 119
Study 15778928 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal glucose concentration (G (b)) assigned the value of fasting plasma glucose concentration (G (fast))
Number of subjects: 15
Study 15778928 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal glucose concentration (G (b)) assigned the value of plasma glucose concentration 180 minutes after the start of the IVGTT (G (180))
Number of subjects: 15
Study 12835077 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel drug delivery system with coarse dispersion (average particle size 1-150 microm)
Number of subjects: 0
Study 12835077 — intervention group
Group type: COMPARATOR
Intervention: Microemulsion system
Number of subjects: 0
Study 11391543 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily for 3 years
Number of subjects: 58
Study 9164421 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0
Study 9164421 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 0
Study 9164421 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 0
Study 7970428 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril-enhanced 99Tcm-MAG3 renal scintigraphy
Number of subjects: 27
Study 2960494 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg twice daily
Number of subjects: 39
Study 2960494 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 39
Study 31201949 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study 31201949 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 0
Study 31201949 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 0
Study 26865083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% continuous wound infiltration (8 ml/h)
Number of subjects: 39
Study 26865083 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 39
Study 26865083 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received intraoperative low-dose ketamine, acetaminophen, NSAIDs, nefopam, and morphine PCA
Number of subjects: 39
Study 26806502 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25‐50 mg)
Number of subjects: 335
Study 26806502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study 22985207 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg·kg(‐1) intranasally (group N)
Number of subjects: 62
Study 22985207 — intervention group
Group type: COMPARATOR
Intervention: 1 μg·kg(‐1) buccally (group B)
Number of subjects: 62
Study 21235700 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin (5/10 mg)
Number of subjects: 738
Study 21235700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 738
Study 19373213 — intervention group
Group type: EXPERIMENTAL
Intervention: RTGT
Number of subjects: 77
Study 19373213 — intervention group
Group type: COMPARATOR
Intervention: CHSC
Number of subjects: 77
Study 17011500 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0557, 1 mg/day
Number of subjects: 1661
Study 17011500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1661
Study 15233971 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 minute occlusion
Number of subjects: 20
Study 15233971 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 minutes occlusion
Number of subjects: 20
Study 15233971 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 minutes occlusion
Number of subjects: 20
Study 11189689 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment interventions (three increasingly intensive interventions)
Number of subjects: 0
Study 11189689 — intervention group
Group type: EXPERIMENTAL
Intervention: Minority-focused PLCO trial screening center
Number of subjects: 0
Study 11189689 — intervention group
Group type: EXPERIMENTAL
Intervention: Study on factors influencing black women's decisions
Number of subjects: 0
Study 11189689 — intervention group
Group type: EXPERIMENTAL
Intervention: Study on psychosocial factors
Number of subjects: 0
Study 9299885 — intervention group
Group type: COMPARATOR
Intervention: Normal alleles
Number of subjects: 111
Study 9299885 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded alleles
Number of subjects: 111
Study 9299885 — intervention group
Group type: EXPERIMENTAL
Intervention: Allele distribution
Number of subjects: 111
Study 9299885 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG repeat stability
Number of subjects: 111
Study 8070826 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine prophylaxis (1.5 mg/kg bolus followed by 2 mg/min infusion)
Number of subjects: 100
Study 8070826 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 100
Study 8070826 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine prophylaxis
Number of subjects: 100
Study 31647464 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-fluorouracil (chemoprevention of KC)
Number of subjects: 0
Study 31647464 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 29482983 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch strategy (2 years of tamoxifen followed by 3 years of aromatase inhibitors)
Number of subjects: 3697
Study 29482983 — intervention group
Group type: COMPARATOR
Intervention: Upfront treatment (5 years of aromatase inhibitors)
Number of subjects: 3697
Study 29482983 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg per day for 5 years)
Number of subjects: 3697
Study 29482983 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (25 mg per day for 5 years)
Number of subjects: 3697
Study 29482983 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg per day for 5 years)
Number of subjects: 3697
Study 29482983 — intervention group
Group type: COMPARATOR
Intervention: Switch strategy
Number of subjects: 3697
Study 29482983 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront treatment
Number of subjects: 3697
Study 29231299 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with dynamic moxibustion
Number of subjects: 55
Study 29231299 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture alone
Number of subjects: 55
Study 24789736 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy for Primary Care (PST-PC)
Number of subjects: 45
Study 24789736 — intervention group
Group type: COMPARATOR
Intervention: Dietary Education Control (DIET)
Number of subjects: 45
Study 22149875 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab plus docetaxel
Number of subjects: 808
Study 22149875 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus trastuzumab plus docetaxel
Number of subjects: 808
Study 20698956 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke volume guided fluid therapy combined with dopexamine (0.5 mcg/kg/min) (SV & DPX group)
Number of subjects: 135
Study 20698956 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke volume guided fluid therapy (SV group)
Number of subjects: 135
Study 20698956 — intervention group
Group type: COMPARATOR
Intervention: Central venous pressure guided fluid therapy (CVP group)
Number of subjects: 135
Study 20698956 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall complication rates
Number of subjects: 135
Study 20698956 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum inflammatory markers
Number of subjects: 135
Study 17668541 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg/g ointment
Number of subjects: 839
Study 17668541 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 839
Study 16055957 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/d) and calcium carbonate (500 mg/d)
Number of subjects: 26
Study 16055957 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol implant (25 mg, replaced every 6 mo)
Number of subjects: 26
Study 16055957 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (500 mg/d) only (Control for alendronate group)
Number of subjects: 26
Study 16055957 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (Control for estradiol group)
Number of subjects: 26
Study 11846888 — intervention group
Group type: EXPERIMENTAL
Intervention: RUL ECT at 5 or 2.5 times seizure threshold
Number of subjects: 40
Study 9973655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebselen (150 mg b.i.d. for 2 weeks)
Number of subjects: 105
Study 9973655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 8849539 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential Acuity Meter (PAM)
Number of subjects: 52
Study 8849539 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillatory Displacement Threshold (ODT)
Number of subjects: 52
Study 8849539 — intervention group
Group type: COMPARATOR
Intervention: Rodenstock Retinometer (RR)
Number of subjects: 52
Study 2279644 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% sodium tetradecyl sulfate (STD)
Number of subjects: 41
Study 2279644 — intervention group
Group type: COMPARATOR
Intervention: 1.6% sodium morrhuate (MOR) diluted with 50% dextrose
Number of subjects: 41
Study 550621 — intervention group
Group type: EXPERIMENTAL
Intervention: diisopropylamine (3 times 200 mg a day)
Number of subjects: 64
Study 550621 — intervention group
Group type: EXPERIMENTAL
Intervention: reserpine (3 times 0.25 mg a day)
Number of subjects: 64
Study 30522912 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-transrectal ultrasound (TRUS) fusion targeted biopsy (FUS-TB)
Number of subjects: 665
Study 30522912 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive registration TRUS targeted biopsy (COG-TB)
Number of subjects: 665
Study 30522912 — intervention group
Group type: EXPERIMENTAL
Intervention: In-bore MRI targeted biopsy (MRI-TB)
Number of subjects: 665
Study 30522912 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 665
Study 30144819 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage protocol
Number of subjects: 40
Study 30144819 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress protocol followed by massage
Number of subjects: 40
Study 30144819 — intervention group
Group type: COMPARATOR
Intervention: Stress protocol
Number of subjects: 40
Study 30144819 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 26897446 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction angle of 60°
Number of subjects: 60
Study 26897446 — intervention group
Group type: COMPARATOR
Intervention: Extraction angle of 90°
Number of subjects: 60
Study 25048381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 1309
Study 25048381 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 1309
Study 23227155 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AER)
Number of subjects: 25
Study 23227155 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RES)
Number of subjects: 25